Aug 09, 2016 11:05 am UTC| Business
MENLO PARK, Calif. and CAMBRIDGE, Mass., Aug. 09, 2016 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) and Editas Medicine, Inc. (Nasdaq:EDIT) today announced a collaboration to explore the delivery of genome editing...
Aug 09, 2016 11:05 am UTC| Business
-Collaboration Brings Together Vector and Ophthalmology Expertise of Adverum with Genome Editing Capabilities of Editas- MENLO PARK, Calif. and CAMBRIDGE, Mass., Aug. 09, 2016 -- Adverum Biotechnologies, Inc....
Aug 09, 2016 11:05 am UTC| Business
CAMBRIDGE, Mass., Aug. 09, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today...
Gaming and Leisure Properties, Inc. Announces Second Quarter 2016 Results
Aug 09, 2016 11:00 am UTC| Business
- Closes Acquisition of Pinnacle Entertainment's (NASDAQ:PNK) Real Estate Assets for $4.8 billion -- Establishes 2016 Third Quarter Guidance and Revises Full Year Guidance -- Declares 2016 Third Quarter Dividend of $0.60...
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
Aug 09, 2016 11:00 am UTC| Business
- Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) - - Positive FDA pre-NDA meeting - NDA for Dravet syndrome and LGS on track for H1 2017 submission - -Conference call today at 8:30 a.m. EDT, 1:30...
Aug 09, 2016 11:00 am UTC| Business
New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patientsPlans include incorporating new formulation into PhaseOut DMD trial OXFORD, United Kingdom, Aug. 09, 2016 -- Summit...
Aug 09, 2016 11:00 am UTC| Business
The study will enroll about 250 patients in Europe and the U.S.The grant will cover a significant portion of the study expenses PLX-PAD was previously selected by the EMA to be developed via the Adaptive Pathways...